Big Names Backers Give Altos $3bn To Pursue Cell Rejuvenation Science
Founders Unveil New Research Powerhouse
Provided with a record $3bn backing from investors and bringing some big names on board, Hal Barron’s new firm Altos Labs wants to “reimagine medical treatments where reversing disease for patients of any age is possible."
You may also be interested in...
Mysterious Retro Biosciences Aims To Extend Human Lifespan By 10 Years With Cellular Anti-Aging Tech
Emerging from stealth mode, the Californian biotech aims to tackle aging processes looks to have some things in common with multi-billion dollar start up Altos.while also looking to legitimize the science of blood plasma transfusions.
Silicon Valley Bank data show a pullback in crossover financings but an increase in seed and series A venture capital rounds. In recent private company financings, CRO Novotech raised $760m. In public company financings, Eleusis will merge with a SPAC and the Bausch + Lomb IPO is on file with the SEC.
As Barron departs for new rejuvenation-focused biotech Altos Labs, GSK will be under pressure to ensure its R&D can continue to produce green shoots.